Suchergebnisse - "Drug Therapy, Combination"

PubPharm (709)

1

Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment

enthalten in: Journal for immunotherapy of cancer | 2024

von Raguz, J. | Pinto, C. | Pölzlbauer, T. | +13

2

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics

enthalten in: Journal for immunotherapy of cancer | 2024

von Phoon, Y. | Lopes, J. | Pfannenstiel, L. | +9

3

Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention : A Systematic Review and Network Meta-Analysis

enthalten in: Diabetes & metabolism journal | 2024

von Kim, J. | Lee, G. | Park, K. | +1

4

Analysis of East Asia subgroup in Study 309/KEYNOTE-775 : lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

enthalten in: Journal of gynecologic oncology | 2024

von Yonemori, K. | Fujiwara, K. | Hasegawa, K. | +17

5

rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors

enthalten in: Journal for immunotherapy of cancer | 2024

von Lee, M. | Im, S. | Baek, S. | +9

6

An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy

enthalten in: Journal for immunotherapy of cancer | 2024

von Wang, S. | Li, Y. | Xu, C. | +2

7

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1% : results from a multicenter, open-label, phase 2 trial

enthalten in: Journal for immunotherapy of cancer | 2024

von Ren, S. | Wang, X. | Han, B. | +19

8

Initial Combination Therapy in Type 2 Diabetes

enthalten in: Endocrinology and metabolism (Seoul, Korea) | 2024

von Kim, J. | Kim, N.

9

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

enthalten in: Journal for immunotherapy of cancer | 2024

von Carbone, D. | Ciuleanu, T. | Schenker, M. | +23

10

SAFFRON-103 : a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma

enthalten in: Immunotherapy | 2024

von Wang, X. | Pan, H. | Cui, J. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[71]